Everest Group PEAK Matrix® Assessment 2026
Everest Group assessed 34 pharma R&D IT service providers. Download the report to see why Excelra is one of 9 Leaders, and what R&D buyers now expect from their technology partners.
Why Everest Group rated Excelra a Leader
Four strengths stood out in Everest Group’s assessment.
Proprietary scientific data
GOSTAR™ brings more than 37 million curated bioactivity records across diverse molecular modalities, with source-level provenance, ready for AI and ML.
Verticalized scientific AI
Accelerators such as CelraAI, plus productized offerings in multimodal analytics, scientific knowledge retrieval and regulatory intelligence, with 10+ PoCs in the pipeline.
Deeper bioinformatics talent
The acquisition of BISC Global strengthened our bioinformatics team and brought us closer to clients in Europe.
A connected ecosystem
Partnerships across AWS, Microsoft Azure, Google Cloud, LabWare, LabVantage, Sapio Sciences and IDBS.
The science-led specialist in the Leader tier
Everest Group’s PEAK Matrix® rates providers on market impact and on vision and capability. Most Leaders are large global IT and consulting firms. Excelra earned its place through scientific data, scientific AI and bioinformatics depth, the qualities Everest Group’s research finds buyers now value most.
“Science comes first. It is a conviction we have never compromised, and this recognition validates that belief. In pharma R&D, scientific depth now carries as much weight as scale.”
-Anandbir Brar, CEO, Excelra
Inside the report
- Excelra’s Leader positioning on the PEAK Matrix®
- The strengths Everest Group highlighted
- Market size, growth and what is driving pharma R&D IT demand
- The criteria buyers now use to choose R&D IT partners
- Why scientific AI still struggles to move from pilot to production
“As pharmaceutical enterprises seek to improve R&D productivity amid increasing scientific complexity, they are prioritizing partners that combine deep scientific and functional expertise with strong data, AI, and platform capabilities,” says Durga Ambati, Vice President at Everest Group. “Excelra stands out through its proprietary scientific datasets, including GOSTAR, which support structure–activity intelligence, compound screening, and lead optimization. Its verticalized scientific AI proposition further combines multimodal data and analytics, scientific knowledge retrieval, and regulatory intelligence. These strengths have positioned Excelra as a Leader in Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix® Assessment 2026.”
-Durga Ambati, Vice President, Everest Group
See the full assessment
Excelra’s Leader profile, market trends and buyer priorities from Everest Group, in one report.
Source: Everest Group (2026). Report licensed to Excelra.
"*" indicates required fields
